- Home
- AKBA vs USCB Comparison
AKBA vs USCB Comparison
Compare AKBA & USCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- USCB
- Stock Information
- Founded
- AKBA 2007
- USCB 2002
- Country
- AKBA United States
- USCB United States
- Employees
- AKBA N/A
- USCB N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- USCB Major Banks
- Sector
- AKBA Health Care
- USCB Finance
- Exchange
- AKBA Nasdaq
- USCB Nasdaq
- Market Cap
- AKBA 336.2M
- USCB 382.1M
- IPO Year
- AKBA 2014
- USCB 2021
- Fundamental
- Price
- AKBA $1.82
- USCB $20.17
- Analyst Decision
- AKBA Strong Buy
- USCB Buy
- Analyst Count
- AKBA 2
- USCB 4
- Target Price
- AKBA $5.75
- USCB $16.13
- AVG Volume (30 Days)
- AKBA 2.4M
- USCB 49.7K
- Earning Date
- AKBA 11-07-2024
- USCB 10-31-2024
- Dividend Yield
- AKBA N/A
- USCB 1.00%
- EPS Growth
- AKBA N/A
- USCB 13.14
- EPS
- AKBA N/A
- USCB 1.04
- Revenue
- AKBA $169,879,000.00
- USCB $71,791,000.00
- Revenue This Year
- AKBA N/A
- USCB N/A
- Revenue Next Year
- AKBA $6.13
- USCB $15.26
- P/E Ratio
- AKBA N/A
- USCB $19.12
- Revenue Growth
- AKBA N/A
- USCB 10.04
- 52 Week Low
- AKBA $0.80
- USCB $10.25
- 52 Week High
- AKBA $2.48
- USCB $21.86
- Technical
- Relative Strength Index (RSI)
- AKBA 56.59
- USCB 72.13
- Support Level
- AKBA $1.76
- USCB $19.03
- Resistance Level
- AKBA $2.02
- USCB $20.98
- Average True Range (ATR)
- AKBA 0.11
- USCB 1.06
- MACD
- AKBA -0.02
- USCB 0.09
- Stochastic Oscillator
- AKBA 40.00
- USCB 75.36
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About USCB USCB Financial Holdings Inc.
USCB Financial Holdings Inc is a community bank. Through its network of branches and its online banking platform, it offers customers a wide range of financial products and services such as Personal and Business Checking, Savings, Credit Cards, and Real Estate Loans.